The protein CD11b has been implicated in the various adhesion-related interactions of cells such as monocytes, macrophages, natural killer (NK) cells, and granulocytes. It is part of a heterodimer that consists of CD11b and CD18. It also modulates the uptake of complement-coated particles within the cell. It is commonly used as a microglial marker in tissues derived from the nervous system. Immunoblotting experiments with the CD11b antibody from Wong’s lab indicate that hypoxia-inducible factor 1 (HIF-1) critically regulates breast cancer metastases by priming the lung niche microenvironment before the arrival of secondary tumor cells1. The same group used the CD11b antibody in their follow-up studies where they monitored the effects of two distinct HIF inhibitors – digoxin and acriflavine – on niche formation2.
Western Blot: CD11b Antibody
They found that both drugs were effective in their orthotopic breast cancer model and hope to develop them as aggressive therapeutics. Studies out of the Mayo Clinic were focused on Alzheimer’s disease (AD) and employed the CD11b antibody in both immunoblotting and flow cytometry assays to methodically dissect and assess the contribution of murine IL-6 (mIL-6) in modulating amyloid beta deposition3. Welt’s group at Harvard examined the role of leukocytes in stent-induced arterial injury - with the help of a CD11b antibody, they were able to establish a central role for neutrophils, and not macrophages, in restenosis4. Lastly, a CD11b antibody allowed Yen et al to demonstrate that the combination of activated protein C and rapamycin treatment enabled downregulation of sepsis-induced lung injury, allowing functional healing and improved survival5.
Novus Biologicals offers CD11b reagents for your research needs including:
PMIDs
